- Home
- M vs RNA Comparison
M vs RNA Comparison
Compare M & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- M
- RNA
- Stock Information
- Founded
- M 1830
- RNA 2012
- Country
- M United States
- RNA United States
- Employees
- M N/A
- RNA N/A
- Industry
- M Department/Specialty Retail Stores
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- M Consumer Discretionary
- RNA Health Care
- Exchange
- M Nasdaq
- RNA Nasdaq
- Market Cap
- M 4.8B
- RNA 4.0B
- IPO Year
- M N/A
- RNA 2020
- Fundamental
- Price
- M $19.46
- RNA $69.84
- Analyst Decision
- M Hold
- RNA Buy
- Analyst Count
- M 10
- RNA 20
- Target Price
- M $15.72
- RNA $69.26
- AVG Volume (30 Days)
- M 6.9M
- RNA 9.1M
- Earning Date
- M 11-25-2025
- RNA 11-07-2025
- Dividend Yield
- M 3.76%
- RNA N/A
- EPS Growth
- M 304.55
- RNA N/A
- EPS
- M 1.77
- RNA N/A
- Revenue
- M $22,701,000,000.00
- RNA $10,729,000.00
- Revenue This Year
- M N/A
- RNA N/A
- Revenue Next Year
- M N/A
- RNA $108.26
- P/E Ratio
- M $10.99
- RNA N/A
- Revenue Growth
- M N/A
- RNA 1.23
- 52 Week Low
- M $9.76
- RNA $21.51
- 52 Week High
- M $19.99
- RNA $70.51
- Technical
- Relative Strength Index (RSI)
- M 64.78
- RNA 79.50
- Support Level
- M $19.24
- RNA $69.50
- Resistance Level
- M $19.99
- RNA $69.91
- Average True Range (ATR)
- M 0.51
- RNA 1.51
- MACD
- M 0.06
- RNA 1.77
- Stochastic Oscillator
- M 79.21
- RNA 91.50
About M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's name, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.